Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
Viral clade is associated with severity of symptomatic genotype 3 hepatitis E virus infections in Belgium, 2010-2018.
Peeters M, Schenk J, De Somer T, Roskams T, Locus T, Klamer S, Subissi L, Suin V, Delwaide J, Stärkel P, De Maeght S, Willems P, Colle I, Van Hoof M, Van Acker J, Van Steenkiste C, Moreno C, Janssens F, Reynders M, Steverlynck M, Verlinden W, Lasser L, de Galocsy C, Geerts A, Maus J, Gallant M, Van Outryve S, Marot A, Reynaert H, Decaestecker J, Bottieau E, Schreiber J, Mulkay JP, de Goeij S, Salame M, Dooremont D, Dastis SN, Boes J, Nijs J, Beyls J, Hens N, Nevens F, Van Gucht S, Vanwolleghem T; Belgian Association for the Study of the Liver. Peeters M, et al. Among authors: lasser l. J Hepatol. 2023 Jan;78(1):67-77. doi: 10.1016/j.jhep.2022.08.033. Epub 2022 Sep 6. J Hepatol. 2023. PMID: 36075495 Free article.
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation.
Nevens F, Gustot T, Laterre PF, Lasser LL, Haralampiev LE, Vargas V, Lyubomirova D, Albillos A, Najimi M, Michel S, Stoykov I, Gordillo N, Vainilovich Y, Barthel V, Clerget-Chossat N, Sokal EM. Nevens F, et al. Among authors: lasser ll. JHEP Rep. 2021 Apr 18;3(4):100291. doi: 10.1016/j.jhepr.2021.100291. eCollection 2021 Aug. JHEP Rep. 2021. PMID: 34169246 Free PMC article.
Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium: an observational study.
Bourgeois S, Mulkay JP, Cool M, Verhelst X, Robaeys G, Lasser L, Lefebvre V, Colle I, Van Steenkiste C, Decaestecker J, Coulon S, Venken K, Vanwolleghem T. Bourgeois S, et al. Among authors: lasser l. Acta Gastroenterol Belg. 2021 Jan-Mar;84(1):33-41. doi: 10.51821/84.1.851. Acta Gastroenterol Belg. 2021. PMID: 33639691 Free article.
Hepatitis C virus (HCV) prevalence estimation in the adult general population in Belgium : a meta-analysis.
Muyldermans G, Bielen R, Botterman R, Bourgeois S, Colle I, Deressa B, Devolder G, Horsmans Y, Hutse V, Lanthier N, Lasser L, Platteau S, Robaeys G, Suin V, Verhelst X, Van Vlierberghe H, Van Baelen L. Muyldermans G, et al. Among authors: lasser l. Acta Gastroenterol Belg. 2019 Oct-Dec;82(4):479-485. Acta Gastroenterol Belg. 2019. PMID: 31950802 Free article.
Giant fibrovascular polyp of the esophagus.
François S, Waldbillig C, Lasser L, Ngassa M, Khamaktchian M. François S, et al. Among authors: lasser l. Gastrointest Endosc. 2020 Feb;91(2):442-443. doi: 10.1016/j.gie.2019.09.002. Epub 2019 Sep 6. Gastrointest Endosc. 2020. PMID: 31499045 No abstract available.
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators. Merle P, et al. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4. Lancet Gastroenterol Hepatol. 2019. PMID: 30954567 Free article. Clinical Trial.
42 results